COMPANY

Azurity Pharmaceuticals

FDA-approved therapeutic company Clinical Phase 3

Azurity is a privately held specialty pharmaceutical company with medicines across 11 therapeutic areas, operating in more than 50 countries. From company website Source · Oct 12, 2026

Keywords: Seizures Focal Seizures Partial Onset Seizure Partial Seizure Disorder Partial Seizure Partial Epilepsies Epilepsy Male Hypogonadism

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

2026-09 Trial start Phase 4: Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures source ↗
2026-02 Trial start Phase 4: Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men source ↗

Upcoming milestones

2027-06 (ESTIMATED) · Phase 4 · Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men · NCT07328542
2027-09 (ESTIMATED) · Phase 4 · Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures · NCT06534502

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06534502	Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures	Phase 4	Not yet recruiting	2026-09	2027-09 (estimated)
NCT07328542	Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men	Phase 4	Not yet recruiting	2026-02	2027-06 (estimated)